A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
H9H-MC-JBEG - ClinicalTrials.gov - NCT02734160
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Pancreatic CancerWhat the trial is testing?
Durvalumab, GalunisertibCould I receive a Placebo?
NoEnrollment Goal
37Trial Dates
Jun 15, 2016 - Apr 17, 2019How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo